Letermovir and Lopinavir and ritonavir
Determining the interaction of Letermovir and Lopinavir and ritonavir and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with inducers of the P-glycoprotein (P-gp) efflux transporter and/or the uridine diphosphate glucuronosyltransferase (UGT) enzymes may decrease the plasma concentrations of letermovir according to the product labeling. Because letermovir is a substrate of P-gp and UGT 1A1 and 1A3, induction of the efflux transporter and metabolic enzymes may theoretically increase the clearance of letermovir. Concomitant use of rifampin initially resulted in a clinically insignificant increase in letermovir plasma concentrations (due to inhibition of organic anion transporting polypeptide [OATP] 1B1/3 and/or P-gp), followed by clinically significant decreases in letermovir plasma concentrations with continued rifampin coadministration (due to induction of P-gp/UGT). MANAGEMENT: Letermovir product labeling recommends avoiding concomitant use with inducers of P-gp and/or UGT. References Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0 "Product Information. Prevymis (letermovir)." Merck & Company Inc, Whitehouse Station, NJ. Cerner Multum, Inc. "Canadian Product Information." O 0 (2015):
Professional:GENERALLY AVOID: Coadministration with inducers of the P-glycoprotein (P-gp) efflux transporter and/or the uridine diphosphate glucuronosyltransferase (UGT) enzymes may decrease the plasma concentrations of letermovir according to the product labeling. Because letermovir is a substrate of P-gp and UGT 1A1 and 1A3, induction of the efflux transporter and metabolic enzymes may theoretically increase the clearance of letermovir. Concomitant use of rifampin initially resulted in a clinically insignificant increase in letermovir plasma concentrations (due to inhibition of organic anion transporting polypeptide [OATP] 1B1/3 and/or P-gp), followed by clinically significant decreases in letermovir plasma concentrations with continued rifampin coadministration (due to induction of P-gp/UGT).
MANAGEMENT: Letermovir product labeling recommends avoiding concomitant use with inducers of P-gp and/or UGT.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- "Product Information. Prevymis (letermovir)." Merck & Company Inc, Whitehouse Station, NJ.
- Cerner Multum, Inc. "Canadian Product Information." O 0 (2015):
Generic Name: letermovir
Brand name: Prevymis
Synonyms: Letermovir (Oral), Letermovir (oral/injection)
Generic Name: lopinavir / ritonavir
Brand name: Kaletra
Synonyms: Lopinavir and Ritonavir
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Letermovir-Lopinavir and Ritonavir Oral Solution
- Letermovir-Lopinavir and Ritonavir Solution
- Letermovir-Lopinavir and Ritonavir Tablets
- Letermovir-Lopreeza
- Letermovir-Lopressor
- Letermovir-Lopressor (Metoprolol Injection)
- Lopinavir and ritonavir-Letermovir Injection
- Lopinavir and ritonavir-Letermovir Intravenous
- Lopinavir and ritonavir-Letermovir oral/injection
- Lopinavir and ritonavir-Letermovir Tablets
- Lopinavir and ritonavir-Letrozole
- Lopinavir and ritonavir-Letrozole and ribociclib